Skip to main content

Table 1 Baseline characteristics of the study population

From: Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B

Parameters TAF 25 mg TDF 300 mg ETV 0.5 mg P value
(n = 10) (n = 10) (n = 20)
Age (years) 40.56 ± 11.18 41.00 ± 12.64 39.72 ± 9.13 0.901
Male, n (%) 10 (100) 10 (100) 20 (100) 1.0
Liver cirrhosis 8 (80) 7 (70) 13 (65) 0.901
ALT (U/L) 351.10 (308.72) 203.67 (173.61) 385.85 (519.33) 0.588
AST (U/L) 263.78 (242.47) 156.89 (84.39) 382.61 (397.06) 0.707
TBIL (μmol/L) 362.93 (178.62) 321.10 (127.87) 240.44 (144.35) 0.174
Albumin (g/L) 31.32 (3.71) 30.90 (4.38) 32.23 (4.19) 0.905
Urea (mmol/L) 5.71 (3.09) 5.74 (2.70) 5.86 (3.23) 0.948
Creatinine (μmol/L) 77.22 (34.20) 66.22 (22.08) 66.00 (24.27) 0.458
eGFR (mL/min/1.73m2) 112.76 (41.47) 150.23 (30.12) 112.34 (68.85) 0.274
INR 1.71 (0.32) 2.08 (0.87) 2.13 (0.63) 0.179
WBC (× 109/L) 6.22 (1.82) 7.28 (3.48) 6.91 (3.54) 0.819
PLT (×109/L) 115.11 (60.48) 97.44 (113.02) 98.33 (63.09) 0.168
Serum sodium, mmol/L 137.11 (2.32) 135.11 (4.96) 135.16 (7.06) 0.784
HbeAg positive 8 (80) 8 (80) 15 (75) 0.931
LogHBV DNA (log IU/mL) 4.80 (1.93) 5.81 (1.87) 5.13 (1.89) 0.458
MELD score 21.56 (5.66) 21.33 (7.28) 20.50 (5.40) 0.943
CTP score 10.22 (1.44) 10.78 (1.64) 10.44 (1.56) 0.151
CTP class(B/C) 3/7 1/9 1/19 0.202
NUC-naïve 7 (70) 2 (20) 15 (75) 0.019
Follow-up (wk) 68.50 (48–92) 64.50 (51–95) 69.00 (50–95) 0.938
  1. Data are expressed as mean ± standard deviation (SD), number (percentage) or median (range)
  2. ETV entecavir, TDF tenofovir disoproxil fumarate, TAF tenofovir alafenamide, ALT alanine aminotransferase, AST aspartate Aminotransferase, TBIL total bilirubin, INR international normalized ratio, WBC white blood cell count, PLT platelet count, HBeAg Hepatitis B e antigen, HBV hepatitis B virus, MELD Model for End-stage Liver Disease, CTP Child-Turcotte-Pugh, NUC nucleos(t) ide analogues